Skip to main content
. 2017 Apr 7;8(24):38193–38213. doi: 10.18632/oncotarget.16942

Figure 8. HGF/MET inhibition restores sensitivity to angiogenesis inhibitors in human HGF knock-in SCID mice.

Figure 8

A. HCT-116-luc cells were injected orthotopically into human HGF knock-in (hHGF KI) SCID mice, and tumor-bearing animals were randomly assigned to 8 treatment arms: control (CTR), 15 mg/kg bevacizumab (BEV), 10 mg/kg tivozanib (TIV), 40 mg/kg JNJ-38877605 (JNJ), 20 mg/kg ficlatuzumab (FCL), 15 mg/kg bevacizumab plus 40 mg/kg JNJ-38877605 (BEV+JNJ), 10 mg/kg tivozanib plus 40 mg/kg JNJ-38877605 (TIV+JNJ), and 10 mg/kg tivozanib plus 20 mg/kg ficlatuzumab (TIV+FCL). Tumor growth was followed over time by in vivo bioluminescence (IVBL). Results are shown in 2 different graphs for clarity. B. Same as in A but using HT-29-luc cells. Values represent mean ± SEM. Statistical significance was calculated using a Student's T-test (B, n = 7).